Asthma is the most common chronic condition in children worldwide. It affects daytime activities, sleep and school attendance and causes anxiety to parents, families and other carers. The quality of asthma diagnosis and management globally still needs substantial improvement. From infancy to the tee...nage years, there are age-specific challenges, including both underdiagnosis and overdiagnosis with stigma-related barriers to treatment in some cultures and in adolescents. The Paediatric Asthma Project Plan has been initiated to strengthen diagnosis and management of asthma. This encompasses a vision for the next 10–15 years, building on the knowledge and experience from previous educational projects. It will take into account the educational needs of patients, carers and healthcare professionals as well as the accessibility and affordability of medication, particularly in low and middle-income countries where the prevalence of asthma is rising more rapidly. This overview presents a first step for those involved in the diagnosis and management of childhood asthma to strengthen care for children globally.
more
Bonchial asthma is the most common chronic respiratory disease in the world. In Kenya, it has been estimated that about 7.5% of the Kenyan population, nearly 4 million people, are currently living with asthma. Many cases tend to be underdiagnosed and undertreated which leads to high levels of morbid...ity and avoidable deaths. The consequences of poorly controlled asthma, including physical, mental, social, and economic impacts, are magnified in the poor on account of poor access to asthma services and sub-optimal quality of those services. With these guidelines, Kenya's Ministry of Health aims to work towards embedding asthma care in Universal Health Care (UHC) to ensure that quality asthma services are available in primary care settings with
referral networks strengthened for those who may require secondary and tertiary care. These national asthma guidelines will also ensure that treatment for asthma is standardized in both the public and the non-state health care sector.
more
As our world changes, so too does the burden of disease. Globalisation, evolving trade and consumption patterns, and increased access to life-saving medical care are just some of the factors that have transformed the global health landscape.
Mpox is an emerging zoonotic disease caused by the mpox virus, a member of the Orthopoxvirus genus closely related to the variola virus that causes smallpox. Mpox was first discovered in 1958 when outbreaks of a pox-like disease occurred in monkeys kept for research. The first human case was recorde...d in 1970 in the Democratic Republic of the Congo (DRC) during a period of intensified effort to eliminate smallpox and since then the infection has been reported in a number of African countries. Mpox can spread in humans through close contact, usually skin-to-skin contact, including sexual contact, with an infected person or animal, as well as with materials contaminated with the virus such as clothing, beddings and towels, and respiratory droplets in prolonged face to face contact. People remain infectious from the onset of symptoms until all the lesions have scabbed and healed. The virus may spread from infected animals through handling infected meat or through bites or scratches. Diagnosis is confirmed by polymerase chain reaction (PCR) testing of material from a lesion for the virus’s DNA. Two separate clades of the mpox virus are currently circulating in Africa: Clade I, which includes subclades Ia and Ib, and Clade II, comprising subclades IIa and IIb. Clade Ia and Clade Ib have been associated with ongoing human-to-human transmission and are presently responsible for outbreaks in the Democratic Republic of the Congo (DRC), while Clade Ib is also contributing to outbreaks in Burundi and other countries.
In 2022‒2023 mpox caused a global outbreak in over 110 countries, most of which had no previous history of the disease, primarily driven by human-to-human transmission of clade II through sexual contact. In just over a year, over 90,000 cases and 150 deaths were reported to the WHO. For the second time since 2022, mpox has been declared a global health emergency as the virus spreads rapidly across the African continent. On 13 Aug 2024, Africa CDC declared the ongoing mpox outbreak a Public Health Emergency of Continental Security (PHECS), marking the first such declaration by the agency since its inception in 2017.7 This declaration empowered the Africa CDC to lead and coordinate responses to the mpox outbreak across affected African countries. On August 14, 2024, the WHO declared the resurgence of mpox a Public Health Emergency of International Concern (PHEIC) emphasizing the need for coordinated international response.
As of August 2024, Mpox has expanded beyond its traditional endemic regions, with new cases reported in countries including Sweden, Thailand, the Philippines, and Pakistan. Sweden has confirmed its first case of Clade 1 variant, which has been rapidly spreading in Africa, particularly in DRC. The emergence of this new variant raises concerns about its potential for higher lethality and transmission rates outside Africa.
more
International Journal of Science Annals DOI 10.26697/ijsa.2018.1-2.05; UDC 159.9.072(477)
Estudio de Mercado sobre Medicamentos
El Programa Nacional de Chagas ha definido la utilización de dos medicamentos para el tratamiento de la Enfermedad de Chagas Crónico Reciente Infantil (en niños de 9 meses a menor de 15 años); el benznidazol (BNZ) que será utilizado como medicamento de primera elección en todos los casos con d...iagnóstico serológico positivo confirmado y el nifurtimox (NFT) que será utilizado como segunda alternativa en aquellos casos que hubieran presentado reacciones adversas graves al benznidazol, e indiquen un cambio de conducta.
more
WHO Medical Devices Donations - FRENCH Version - Les dispositifs médicaux, en particulier, sont indispensables pour la prévention, le diagnostic et le traitement des maladies et la réadaptation des patients. Ces documents s’adressent aux ingénieurs biomédicaux, administrateurs de la santé, b...ailleurs de fonds, organisations non gouvernementales et établissements universitaires concernés par les technologies de la santé au niveau du district, national, régional ou mondial.
more
Rapport de plaidoyer Mars 2011
303100 03/2011 E 1,000
Rapport sur les populations clés.
. MSF Essential Drugs Guidelines دليل عملي موجه للأطباء والصيادلة والممرضين والمساعدين الطبيين
Le panorama du paludisme a profondement changé durant la dernière décénnie. Les financements ont augmenté, les outils permettant de sauver des vies ont été mis en œuvre à plus grande échelle, la charge du paludisme a diminué et un nombre grandissant de pays envisagent son élimination.
...>
Ce cadre actualisé fait le point sur les outils, les activités et les stratégies nécessaires pour atteindre l'élimination du paludisme et empêcher la reprise de la transmission dans les pays, quelle que soit l'étape à laquelle ils se trouvent sur la route menant à l'élimination ou l’intensité de la transmission. Le cadre est destiné à servir de référence pour élaborer des plans stratégiques d’élimination du paludisme au niveau national et doit être adapté aux contextes locaux.
more
Introduction
Chapitre A.6
Edition en français Traduction : Cristina Constantin Sous la direction de : Priscille Gérardin Avec le soutien de la SFPEADA
Washington, D.C., ÉUA, du 23 au 27 septembre 2018
Point 8.3 de l'ordre du jour provisoire
CD56/INF/3 14 juillet 2018
Original: anglais
L'antibiorèsistance constitue actuellment un problème de santè puplique en Tunisie. En effet, depuis une quinzaine d'anneés, notre pays fait face á un accroissment global des rèsistances bactériennes aux agents antimicrobiens. Ce phénoméne qui concerne également la majorité des pays, est ...dû á l'apparition et l'extension de nouveaux mécanismes de résistance, rendant inefficaces les traitements actuellment disponibles.
République Tunienne - Ministére de la santé
more